SELLAS Life Sciences Group, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.52%
vs ±9.4% implied · ×0.70
shaded = implied · ▲▼ = realized
Linked news
Bull3
Bear1
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $222.4M | 14.53% | +23.54% |
| Susquehanna International | $197.7M | 12.92% | +49.16% |
| State Streetindex-like | $191.8M | 12.53% | +54.79% |
| Vanguardindex-like | $121.4M | 7.93% | +9.30% |
| Frigate Ventures | $105.5M | 6.89% | new |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $222.4M | 14.53% | +23.54% |
| Susquehanna International | $197.7M | 12.92% | +49.16% |
| State Streetindex-like | $191.8M | 12.53% | +54.79% |
| Vanguardindex-like | $121.4M | 7.93% | +9.30% |
| Frigate Ventures | $105.5M | 6.89% | new |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of SELLAS Life Sciences Group, Inc.'s 5 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of SELLAS Life Sciences Group, Inc.'s 5 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
SELLAS Life Sciences Group, Inc.
9.06
+0.19 · +2.14%
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
—
Expected move
Inputs8Q avg ±7.3%·×1.90·rich
straddle ±24.7%
spot 8.87exp Nov 13ATM strike 9ATM straddle 2.57IV 218%